Late last week, AllThingsD reported hearing that Twitter co-founder Biz Stone was close to launching a new mobile startup called Jelly. Stone confirmed Monday that he is working full time on the startup, but says that it won’t be launching anytime soon.
“News of Jelly emerged unexpectedly early so I’ll wait a bit to share more about the team,” Stone said in a blog post on the Jelly website. “In the meantime, I’ll say this. Jelly will be for everybody, it will be developed first and foremost for mobile devices, and it will be free. But, it won’t be ready for a while.”
Stone stayed extremely vague about what kind of app Jelly will work on, other than to suggest that it will help people “do good,” and that it will be free and developed “first and foremost for mobile devices.”
Stone left Twitter in mid-2011 and has since been working with Twitter co-founder Ev Williams on a startup incubator called the Obvious Corporation, which has helped launch several projects including Medium and Branch. However, it looks like Stone will be stepping aside from his role at the company to focus on Jelly. “Personally, Jelly will command my full attention aside from some advisory roles elsewhere,” Stone wrote.
Jelly will be based in San Francisco and the company has not received any outside funding yet.
SAN FRANCISCO — Those in the mobile gaming industry, whether developers, publishers, or investors, are at odds about whether Android is a good platform to develop on and whether it will grow.
“Today, I think 26 percent of developers prefer working with Android,” said PlayJam founder Jasper Smith during a panel on the future of mobile gaming today at the Game Developers Conference.
“My prediction is in a couple of years, that’s going to be 60 percent.”
Android currently has the most marketshare around the globe in terms of the smartphone market. Because phones are a huge element in the gaming market, anyone who has a smartphone is a potential customer, as Nizar Romdan, the director of ecosystem and media processing division at ARM, noted. It only makes sense that mobile game developers would want to tap into that market.
But not everyone sees Android as a great environment.
“Android is not a great environment — certainly not for graphics. Our programmers loath it,” said Chris Doran, the founder of Geomerics, (which helps developers incorporate light into their games) during the same panel. “We have to do it; it’s pretty dominant. But it’s not good for graphics at all. Google just doesn’t put enough love into it.”
Michael Ludden, the technical marketing manager of Samsung, was quick to point out that people didn’t love developing for iOS at first. But as the tools advanced, so did the love for the platform.
Despite the pain the platforms might cost you, however, the industry experts all seemed to agree that the real cost mobile game developers are going to have to pay attention to is marketing. Because of the app store’s structure, production costs that seem to matter so heavily in console development give way to marketing costs — trying to get your app noticed in the sea that is Google Play or the Apple App Store.
“Just putting your game in the app store isn’t good enough anymore, “said Geomeric’s Doran. “Marketing is unfortunately going to go through the roof.”
The clever chaps at tenga-eggs.co.uk have started selling a smart japanese device called a tenga egg. these little gizmos from our asian brethren are designed for one use fire and forget moments where you want to maximise your personal pleasure.
Your mother probaly told you you would go deaf, your dad that you would go blind, but the facts seem to sugest that regular masturbation and ejaculation is a good way of cutting the risk of prostate cancer.
A new study claims that there is a string benificial effect from masturbating. and althoug nobody loves you like you love yourself,Give them a go, you know you want to…..
Rob Findlay, founder of Gooroo Ltd and a specialist in waiting time dynamics, helps solve an NHS conundrum.
The NHS is in a conundrum. Trusts with a long wait list are fined under the NHS contract if it treats them; or by performance management if it doesn’t.
But there is a solution, albeit a messy one.
From April 2013, the target regime is expected to focus on the waiting list, when 92 % of incomplete pathways must be below 18 weeks.
This year, trusts must tackle the 18-week backlog but by doing so they will probably breach the admitted and non-admitted targets which live on – zombie-like – in the NHS Contract.
In operational terms, those trusts with an 18-week backlog should treat long-waiting patients, a move that is consistent with the four principles of good waiting list management of: treat more urgent patients more quickly; treat patients with similar priority broadly in turn; keep the longest waits to a reasonable level; don’t waste the available capacity.
In planning terms, it is more difficult because there are the zombie targets (based on patients as they are being treated) and the new ones (based on patients who are still waiting) to juggle.
Resolving this is easier – trusts should plan activity and capacity to achieve the more difficult zombie targets.
If all goes well, then the targets muddle should only last for a year, thus freeing up trusts to focus on stopping the long-wait backlogs from building up in the first place.
With surgery, it’s important to take a hands-on approach. The same applies to investing. Third Rock Ventures announced the close of its third fund this morning, $516 million dedicated solely to health care startups.
Third Rock Ventures is a venture capital fund that supports companies working on health IT, science, biotech, and medicine. Fund III will invest in up to 16 companies with a particular focus on the “going convergence” of diagnostics, therapeutics, information technology, and data.
The firm gets deeply involved in the process of building its portfolio companies. Step one is to discover breakthrough research and technology, and then help build “dream teams” of scientists, researchers, and executives to carry out that vision. Third Rock provides its own leadership team during the early stages of a company’s life and then helps recruit more experienced teams down the road.
Since its inception in 2007, Third Rock has raised more than $1.3 billion and invested in 31 companies to date. The firm plays an instrumental role in launching “transformative” companies, “advancing pipelines to the clinic,” and developing/bringing new products to market. Third Rock not only provides financial support but also works closely with industry partners in many different areas: academia, pharmaceutical corporations, genetic researchers, and so on, “to make this visionary science a business reality.”
Third Rock is headquartered in Boston and its team includes more than 40 people. Fund III will also help expand the team. Read the press release.